Want to see CRIS full AI Analyst Report?
Top Page
Curis
(NASDAQ:CRIS)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.52
▼(-13.17% Downside)
Action:Downgraded
Date:10/30/26
The score is held down primarily by weak financial performance: ongoing losses, negative free cash flow, and volatile/declining revenue with elevated financing risk. Technicals add additional pressure with a clear downtrend and negative momentum. The recent PIPE financing modestly supports liquidity/runway but also highlights dilution risk, while valuation metrics offer limited support due to negative earnings and no dividend.
Positive Factors
High Gross Margins
Gross margins of roughly 95–99% indicate that Curis’s underlying product economics can be attractive when revenue is generated. This provides a potentially durable foundation for future oncology programs, although the benefit currently does not offset R&D and operating costs.
Negative Factors
Persistent Unprofitability
Persistent operating and net losses show that Curis has not yet converted its oncology activities into a self-sustaining earnings model. Continued negative operating leverage can consume capital, restrict reinvestment choices, and keep results dependent on future financing or successful development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Gross margins of roughly 95–99% indicate that Curis’s underlying product economics can be attractive when revenue is generated. This provides a potentially durable foundation for future oncology programs, although the benefit currently does not offset R&D and operating costs.
Read all positive factors
Curis (CRIS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.66M
Dividend YieldN/A
Average Volume (3M)237.42K
Price to Earnings (P/E)―
Beta (1Y)3.04
Revenue Growth-62.17%
EPS Growth85.37%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-14.22
Shares Outstanding6,679,229
10 Day Avg. Volume327,522
30 Day Avg. Volume237,417
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.48
Enterprise Value/Market Cap4.84
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$43.00Price Target Upside7066.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-47.14
Revenue Forecast (FY)$1.75M
Curis Business Overview & Revenue Model
Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase ...
Curis Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful clinical progress and clear near‑term milestones — notably advancement of a registrational PCNSL study with the potential for accelerated submissions, initiation and early milestones for a CLL proof‑of‑concept study, encouraging early collaborator data in gastroesophageal cancer, and collaborative/regulatory engagement. Offsetting these positives are a sizable increase in reported net loss (driven by warrant fair‑value changes), higher G&A tied to financing, a cash runway that depends in part on a milestone contingent warrant exercise, and expected enrollment variability in ultra‑orphan indications. On balance, the clinical and regulatory momentum and near‑term data/milestone visibility materially outweigh the financial and enrollment risks described.Positive Updates
Progress on TakeAim Lymphoma (PCNSL) Registrational Study
Continued steady progress on the single-arm registrational TakeAim Lymphoma study in relapsed/refractory primary CNS lymphoma (PCNSL) with an ORR endpoint; company expects the study to support accelerated submissions in the U.S. and Europe and anticipates updated combination data with ibrutinib in the first half of 2027. Enrollment is described as 'on track' despite the ultra-orphan patient population.
Negative Updates
Significant Increase in Net Loss
Net loss widened to $24.2 million ($1.25 per share) in Q1 2026 from $10.6 million ($1.25 per share) in Q1 2025 — a dollar increase of $13.6 million representing a ~128.3% increase year‑over‑year; increase driven primarily by change in fair value of warrant liabilities related to the January 2026 PIPE financing.
Read all updates
Q1-2026 Updates
Positive
Negative
Progress on TakeAim Lymphoma (PCNSL) Registrational Study
Continued steady progress on the single-arm registrational TakeAim Lymphoma study in relapsed/refractory primary CNS lymphoma (PCNSL) with an ORR endpoint; company expects the study to support accelerated submissions in the U.S. and Europe and anticipates updated combination data with ibrutinib in the first half of 2027. Enrollment is described as 'on track' despite the ultra-orphan patient population.
Read all positive updates
Company Guidance
The company provided specific operational and financial guidance: clinically, Curis expects to dose the initial five patients in the TakeAim CLL zanubrutinib combination study by mid‑2026 with initial data expected in December 2026, will evaluate 100 mg and 200 mg emavusertib (having dosed up to 500 mg historically) to satisfy Project Optimus, and plans to provide updated emavusertib/ibrutinib TakeAim Lymphoma (r/r PCNSL) data — and a substantial enrollment update toward potential full enrollment — in the first half of 2027; separately, a gastric/esophageal cohort presented 16 evaluable patients showing a manageable toxicity profile and encouraging preliminary results. Financially, Q1 2026 net loss was $24.2 million ($1.25 per share) versus a $10.6 million loss ($1.25 per share) in Q1 2025 (R&D $6.4M vs $8.5M year‑over‑year; G&A $5.1M vs $4.0M), and Curis had $15.0 million cash and cash equivalents as of March 31, 2026 plus anticipated gross proceeds of up to $20.2 million from exercise of January 2026 Series B PIPE warrants contingent on public announcement of dosing the fifth CLL patient — amounts the company says should fund planned operations into the second half of 2027.Curis Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.31M | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Gross Profit | 4.28M | 9.40M | 10.81M | 9.81M | 9.90M | 10.12M |
| EBITDA | -21.85M | -5.23M | -42.57M | -45.14M | -51.67M | -40.81M |
| Net Income | -21.15M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
Balance Sheet | ||||||
| Total Assets | 18.97M | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Cash, Cash Equivalents and Short-Term Investments | 5.62M | 5.06M | 20.00M | 56.33M | 85.62M | 115.88M |
| Total Debt | 1.04M | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Total Liabilities | 14.28M | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Stockholders Equity | 4.70M | 5.46M | -6.00M | 19.67M | 46.55M | 90.71M |
Cash Flow | ||||||
| Free Cash Flow | -30.59M | -27.20M | -39.56M | -38.43M | -54.75M | -37.62M |
| Operating Cash Flow | -30.59M | -27.20M | -39.56M | -38.43M | -54.34M | -37.62M |
| Investing Cash Flow | 2.50M | 2.50M | 29.44M | 37.79M | 33.02M | -47.90M |
| Financing Cash Flow | 23.02M | 9.77M | 3.44M | 7.58M | 867.00K | -4.17M |
Curis Technical Analysis
Negative
0.60
Price Trends
0.96
Negative
3.28
Negative
9.22
Negative
Market Momentum
-0.21
Negative
23.88
Positive
47.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.96, and below the 200-day MA of 9.22, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 23.88 is Positive, neither overbought nor oversold. The STOCH value of 47.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.
Curis Risk Analysis
Curis disclosed 60 risk factors in its most recent earnings report. Curis reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Curis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $48.11M | 4.25 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.53M | -0.27 | -165.71% | ― | ― | 77.68% | |
44 Neutral | $4.48M | -0.26 | -41.95% | ― | ― | 99.50% | |
42 Neutral | $6.97M | -0.20 | -204.25% | ― | ― | 88.43% | |
40 Underperform | $3.66M | -0.04 | -1035.26% | ― | -62.17% | 85.37% |
* Healthcare Sector Average
CRIS
Curis
0.55
-29.25
-98.16%
ATNM
Actinium Pharmaceuticals
1.53
0.11
7.75%
CLRB
Cellectar Biosciences
1.22
-2.04
-62.58%
NCNA
Nucana
1.04
-2.67
-71.97%
CNSP
CNS Pharmaceuticals
4.77
-2.74
-36.48%
Curis Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Curis Secures PIPE Financing Through Securities Purchase Agreement
Positive
Oct 19, 2026
On October 16, 2026, Curis entered into a private securities purchase agreement with institutional investors to sell 16,666,680 shares of common stock or pre-funded warrants, plus matching common warrants, at an effective combined price of $0.51 p...
Delistings and Listing ChangesRegulatory Filings and Compliance
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring
Neutral
Jul 30, 2026
On July 24, 2026, Curis, Inc. received written notice from Nasdaq that it had regained compliance with the exchange’s minimum bid price rule and was in full compliance with terms set by a Nasdaq Hearings Panel. As a result, Curis will remain...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.